We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Expanded Newborn Screening Program Increases Detection of Congenital Cytomegalovirus

By LabMedica International staff writers
Posted on 22 Sep 2026

Congenital cytomegalovirus is the most common maternal–fetal infection and often goes undetected at birth, despite its potential to cause progressive hearing loss and developmental delays. More...

In the United States, newborn testing is typically prompted by failed hearing screens, symptoms, or maternal concerns, leaving many infections unidentified. Screening practices also vary widely as states and hospitals adopt different policies without unified guidance. A new study now shows that a system-wide newborn screening program substantially increased detection of congenital cytomegalovirus.

Cleveland Clinic Children’s has implemented an expanded newborn screening program for congenital cytomegalovirus (cCMV) across its Ohio locations to identify infected infants earlier in routine care. The initiative, introduced between 2022 and 2025 in newborn nurseries and neonatal intensive care units (NICUs), begins with a swab-based screening test followed, when indicated, by confirmatory urine testing. Findings from the program were published in Pediatrics on September 21, 2026.

During the implementation period, more than 50,000 babies were born at Cleveland Clinic facilities, with nearly 7,500 receiving cCMV screening. Annual testing volume increased from approximately 150 infants per year to more than 2,000. The expanded program identified 34 infants with cCMV, representing about a 2.5-fold increase in detection compared with previous practice.

cCMV screening is not currently universal for all newborns in the United States and is more commonly performed after a failed hearing screen, in symptomatic infants, or when maternal complications raise concern. However, according to the National Institutes of Health, more than 40% of children who later develop cCMV-related hearing loss initially pass their newborn hearing screen. These findings have been cited in support of broader screening approaches that do not rely solely on hearing status.

“Our findings show that this screening is practical and effective. Identifying affected babies earlier allows for monitoring and ultimately treatment, helping to improve long-term outcomes,” said Frank Esper, M.D., senior author and pediatric infectious disease specialist at Cleveland Clinic Children's.

Related Links
Cleveland Clinic Children's


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
HPV Test
Allplex HPV28 Detection
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The AidaBREAST assay integrates multimodal data to provide patient-specific 10-year recurrence risk and individualized predictions of radiation therapy benefit (photo courtesy of PreludeDx)

Validated Test Predicts Recurrence Risk and Radiation Benefit in Early-Stage Breast Cancer

For women with early-stage invasive breast cancer who undergo breast-conserving surgery, clinicians must assess both the risk of locoregional recurrence and the potential benefit of adjuvant radiation therapy.... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: Natera\'s MCED assay analyzes cell-free DNA in blood to screen for multiple cancers (Image Credit: Adobe Stock)

Multi-Cancer Screening Blood Test Gains FDA Breakthrough Designation

Natera Inc.’s (Austin, TX, USA) multi-cancer early detection (MCED) assay has received Breakthrough Device designation (BDD) from the U.S. Food and Drug Administration (FDA). The assay analyzes cell-free... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.